TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

KEEP YOUR PATIENTS ON TRACK WITH TAKHZYRO

Long-term prevention. Long-term support.

TAKHZYRO safety and efficacy was proven in a 6.5-month study and consistent results were seen in a 2.5-year open-label extension study. Takeda is here to support your patient's treatment journey for the long term, with 10+ years of experience treating and providing product support services for people with HAE.1,2

A real TAKHZYRO® patient, Kelly, with her partner and caregiver, Scott, by a lake.
Kelly
Kelly
A real TAKHZYRO® patient, Jack, at work talking with a colleague.
Jack

Remind your patients
why they started
taking TAKHZYRO

Continue to check in—reinforcing the impact effective prevention has had on their lives and their progress since starting TAKHZYRO.

HAE attacks can be unpredictable, debilitating, and even life-threatening. Your patient’s adherence to their HAE preventive treatment plan is the best way to stay ahead of future attacks. Their next HAE attack may be nothing like their last, and it won’t be their last. That’s why it’s so important you remind them to keep taking TAKHZYRO as prescribed so they can continue to see improved outcomes and reimagine their life with HAE.

Considerations for the next check-in with
your patient

HAE is a lifelong condition, and it's important to set specific goals for therapy. Choosing TAKHZYRO allows patients to reach effective prevention when treating this unpredictable disease. Important metrics to track as they progress toward their goals are:

  • Your patient’s HAE attacks. What were their frequency and severity before preventive treatment and now?
  • On-demand medication. How often does your patient use it since taking TAKHZYRO?
  • Check for proper adherence. Is your patient taking TAKHZYRO exactly as prescribed and sticking with their dosing schedule?
Think about your patient’s overall HAE management plan

You and your patient decided together to add TAKHZYRO as a preventive treatment to their management plan to fit their needs. These needs can change over time, so consider these other areas recommended by the HAEA as you revisit their plan:

  • Any other health issues they may have
  • The benefit of keeping a symptom and treatment tracker for review

A treatment tracker is a great tool that can help you and your patient see how their management plan is working. It can also help to identify triggers so you can work with your patient on how to avoid them. Triggers can include4:

  • Stress
  • Hormonal fluctuations
  • Exhaustion
  • Physical pressure
Continue to check in with your patients—reminding them of the impact effective prevention has had on their lives and their progress since starting TAKHZYRO.
OnePath logo.

Personalized product support for patients every step of the way

Remind patients that OnePath® helps people who have been prescribed TAKHZYRO per the approved indication get access to their medication.

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2022. 2. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy. 2022;77(3):979-990. doi:10.1111/all.15011 3. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 4. Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329–336. doi:10.1016/j.anai.2013.08.019